Compare XOMA & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XOMA | SLDB |
|---|---|---|
| Founded | 1981 | 2013 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 471.6M | 498.6M |
| IPO Year | N/A | 2017 |
| Metric | XOMA | SLDB |
|---|---|---|
| Price | $41.56 | $7.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $67.00 | $16.36 |
| AVG Volume (30 Days) | 272.3K | ★ 951.6K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,094,000.00 |
| Revenue This Year | $24.59 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.64 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.29 | $2.52 |
| 52 Week High | $42.81 | $8.87 |
| Indicator | XOMA | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 71.23 | 45.23 |
| Support Level | $24.38 | $5.16 |
| Resistance Level | N/A | $7.96 |
| Average True Range (ATR) | 1.58 | 0.46 |
| MACD | -0.05 | -0.13 |
| Stochastic Oscillator | 76.97 | 6.02 |
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.